Lorundrostat cut systolic BP by 9.6 mm Hg and UACR by 52.2% vs placebo in participants with CKD and uncontrolled hypertension in Launch-HTN.
|Videos|May 10, 2016
Syed Ali Zaidi from Montefiore Medical Center: Great Progress Made in Treating Pregnancy for Congenital Heart Disease Patients
Author(s)Gale Scott
Even the most severe cases of congenital heart disease can be treated to a level where they can safely navigate high risk pregnancies.
Advertisement
Even the most severe cases of congenital heart disease can be treated to a level where they can safely navigate high risk pregnancies.
Syed Ali N. Zaidi, MD, from Montefiore Medical Center discussed what this treatment might include during part 2 of our interview with the doctor in the Bronx. He discussed one case of a patient with Marfan Syndrome who was able to have a child after three open heart procedures.
Advertisement
Related to this article
The ENRICH-AF trial ultimately did not demonstrate edoxaban’s efficacy, highlighting the need for further stroke prevention strategies for this patient population.
A recent MRI analysis of the pivotal OCEANIC-STROKE trial has indicated a complete lack of association between infarct patterns and asundexian’s efficacy.
A new analysis of 4 major trials has revealed the association between lower SBP and higher TTR and the risk of recurrent stroke after intracerebral hemorrhage.
Data from the phase 2a BIRCH trial demonstrated the treatment’s improvements in mRS and NLR, positioning it for a late-phase trial in the future.
A new analysis of the BRIDGE-TNK trial has demonstrated that patients with cardioembolism are more likely to derive benefit than those with large artery atherosclerosis.
Edaravone dexborneol before thrombectomy improved 90-day independence only in LVO stroke patients with clinical-radiological mismatch in TASTE-2.
Alia Galadari, MD, discusses subtle erythema, commonly missed diagnoses, and research gaps to help clinicians recalibrate their approach to skin of color.
Advertisement
Advertisement
Trending on HCPLive
1
eGFR Underestimates CKD in Patients with Cancer, Study Finds
2
The HCPFive: Top News for Healthcare Providers from the Week of 10/18
3
42% on Povetacicept Reach KDIGO-Aligned UPCR Target in RAINIER
4
Kidney Compass: Final 2-Year TELIGAN Data for Telitacicept in IgA Nephropathy
5